: Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk’s Ozempic

The race for weight-loss drugs stepped up Monday after Roche said it would buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion.

Previous post : State Street taking full ownership of India joint venture with HCLTech
Next post Market Snapshot: U.S. stock futures slip following S&P 500’s fresh 2023 high, as bond yields rise